Trials & Filings

Abstral Launches in Japan

Sublingual pain med launched by KHK, Hisamitsu

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Orexo AB‘s partner, Kyowa Hakko Kirin Co., Ltd. (KHK), has launched Abstral in Japan. Abstral is a rapidly-disintegrating, sublingual rapid-acting formulation of fentanyl citrate, a well-established opioid, and is indicated for the management of breakthrough pain in cancer patients. Kyowa Hakko Kirin (KHK) licensed the right for Abstral in Japan in 2003 and has completed a dedicated clinical development program for the product in the territory. Abstral will be jointly distributed by KHK a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters